Danimer Scientific, Inc.
DNMR · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $2 | $3 | $4 | $4 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $3 | $3 | $5 | $5 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 13.1% | -25.4% | -6.6% | – |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -84.8% | -90.5% | -85% | -78.5% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -218.1% | -80.6% | -107.5% | -214.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -253.1% | -297.1% | -266.7% | -360.3% |
| EPS Diluted | -7.2 | -0.19 | -0.26 | -0.39 |
| % Growth | -3,689.5% | 26.9% | 33.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | $0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | $0 |